{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:18:28Z","timestamp":1777475908590,"version":"3.51.4"},"reference-count":121,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:00:00Z","timestamp":1589673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:00:00Z","timestamp":1589673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD098757"],"award-info":[{"award-number":["R01 HD098757"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH113700"],"award-info":[{"award-number":["R01 MH113700"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Depression and Anxiety"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1002\/da.23038","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T02:50:02Z","timestamp":1589770202000},"page":"747-759","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations"],"prefix":"10.1155","volume":"37","author":[{"given":"A. Irem","family":"Sonmez","sequence":"first","affiliation":[{"name":"Department of Psychiatry and PsychologyMayo ClinicRochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar","family":"Almorsy","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and PsychologyMayo ClinicRochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura B.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Division of Research in Patient Services and Clinical Pharmacology, Cincinnati Children's Hospital Medical CenterUniversity of Cincinnati College of MedicineCincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Strawn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral NeuroscienceUniversity of CincinnatiCincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-6503","authenticated-orcid":false,"given":"Paul E.","family":"Croarkin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and PsychologyMayo ClinicRochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,5,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.05.009"},{"key":"e_1_2_9_3_1","volume-title":"Highlights of Prescribing Information Nuplazid\u2122 (pimavanserin) Tablets","author":"Acadia Pharmaceuticals Inc","year":"2016"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2008.10.010"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2010.10.004"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.10.004"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.11.025"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2012.05.001"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318247cd03"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200511000-00001"},{"issue":"3","key":"e_1_2_9_11_1","first-page":"800","article-title":"Neuroprotective effects of LY379268, a selective mGlu2\/3 receptor agonist: Investigations into possible mechanism of action in vivo","volume":"294","author":"Bond A.","year":"2000","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(99)00663-1"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017693029"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1359257"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0108"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)03384-5"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1003"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2016.12.011"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1889-07.2007"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2005.06.003"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms140612458"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6_Suppl_4.233S"},{"issue":"1","key":"e_1_2_9_23_1","article-title":"Efficacy and tolerability of pharmacotherapy for pediatric anxiety disorders: A network meta\u2010analysis","volume":"80","author":"Dobson E. T.","year":"2019","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301178"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001016"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301531"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6185(99)00039-0"},{"key":"e_1_2_9_28_1","unstructured":"European Medicines Agency. (2016).European Medicines Agency: Evaluation of Medicines for Human Use CHMP Assessment Report for Valdoxan. Retrieved fromhttps:\/\/www.ema.europa.eu\/documents\/variation\u2010report\/valdoxan\u2010h\u2010c\u2010915\u2010p46\u20100027\u2010epar\u2010assessment\u2010report_en.pdf"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S102500"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015910792246227"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40303-015-0011-7"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv126"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:CEMN.0000012717.37839.07"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.07.009"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1353156"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(03)00422-3"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.343"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0021"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2012.741588"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12720"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.113357"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/33.7.909"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000000201"},{"issue":"2","key":"e_1_2_9_44_1","first-page":"651","article-title":"Anxiolytic and side\u2010effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors","volume":"284","author":"Helton D. R.","year":"1998","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2010.02.018"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201200058"},{"key":"e_1_2_9_47_1","volume-title":"TIGLUTIK, Highlights of Prescribing Information","author":"ITF Pharma Inc","year":"2018"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4000712"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001551"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.10.868"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112454230"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.1.27"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2012.03.016"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0143fje"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-2025-1"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2010.01.009"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00066-0"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.5b00656"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.11.007"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2018.09.003"},{"key":"e_1_2_9_61_1","unstructured":"Maier G. Lu Q. Blumer J. Robertson B. Zummo J. &Ludwig E.(2011).A pharmacokinetic and safety evaluation of single oral doses of Eszopiclone in pediatric subjects from 6 to 17 years of age with attention deficit hyperactivity disorder and insomnia. Paper presented at the American Academy of Child & Adolescent Psychiatry Annual Meeting (Toronto Canada). Retrieved fromhttps:\/\/www.simulations\u2010plus.com\/assets\/115_poster106_AACAP_eszopiclone_2011oct18.pdf"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(03)00117-3"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(02)00100-6"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.12.2379"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.09.012"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2869.2010.00833.x"},{"key":"e_1_2_9_67_1","unstructured":"Michelson D. Levine L. Dellva M. Mesters P. Schoepp D. Dunayevich E. &Tollefson G.(2005).Clinical studies with mGluR2\/3 agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Paper presented at the Neuropharmacology 49 Supplement 231\u2013279 (conference abstract)."},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(01)02098-5"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2010.46.3.1437247"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2002.1239"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2280-x"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.08R03CR"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.10.022"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3676-1"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0351-6"},{"issue":"1","key":"e_1_2_9_76_1","first-page":"66","article-title":"LY\u2010354740 (Eli Lilly)","volume":"6","author":"Pilc A.","year":"2003","journal-title":"IDrugs"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00115-8"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(94)90299-2"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.65.5.551"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)81203-9"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711000356"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117735769"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2009.15"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.091926"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/31.12.1663"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2017.1298839"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2017.1365392"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-4221"},{"key":"e_1_2_9_89_1","volume-title":"RILUTEK (riluzole) Tablets, LABEL","author":"Sanofi\u2010Aventis U.S. LLC.","year":"2008"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1083328"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1080\/1025389031000146773"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(99)00215-4"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2006.05218.x"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurx.2005.12.005"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01562-X"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318184ff5b"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.02.007"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08433"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2018.05.006"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40473-014-0014-1"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1491966"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.22329"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-013-0344-0"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709990629"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.02.012"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2017.03.035"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2017.08.031"},{"key":"e_1_2_9_108_1","unstructured":"Sunovian Pharmaceuticals Inc. (2012).Eszopiclone 21476 Clinpharm BPCA Clinical Pharmacology Review. Retrieved fromhttps:\/\/www.fda.gov\/files\/drugs\/published\/Eszopiclone\u201021476\u2010Clinpharm\u2010BPCA.pdf"},{"key":"e_1_2_9_109_1","volume-title":"LUNESTA\u2122, Highlights of Prescribing Information","author":"Sunovion Pharmaceuticals Inc","year":"2014"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802608784936700"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(02)00850-X"},{"issue":"2","key":"e_1_2_9_112_1","first-page":"73","article-title":"Gene\u2010environment interactions in mental disorders","volume":"3","author":"Tsuang M. T.","year":"2004","journal-title":"World Psychiatry"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.02.004"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/189307"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2000.00242.x"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007299431"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.097006"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-6391-7_18"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2016.02.007"},{"key":"e_1_2_9_120_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.9.1223"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012383"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620120-00003"}],"container-title":["Depression and Anxiety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fda.23038","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/da.23038","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/da.23038","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/da.23038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:07:40Z","timestamp":1671541660000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/da.23038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,17]]},"references-count":121,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/da.23038"],"URL":"https:\/\/doi.org\/10.1002\/da.23038","archive":["Portico"],"relation":{},"ISSN":["1091-4269","1520-6394"],"issn-type":[{"value":"1091-4269","type":"print"},{"value":"1520-6394","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,17]]},"assertion":[{"value":"2019-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}